InVisionFirst®-Lung Liquid Biopsy Conditions for Medicare Coverage

InVisionFirst®-Lung Liquid Biopsy is a plasma-based, somatic comprehensive genomic profiling test (CGP) intended to assist physicians caring for patients with advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC). In accordance with Medicare's MolDX Noridian LCD L37897, testing is appropriate under the following circumstances:

At diagnosis and untreated: When results for EGFR single nucleotide variants (SNVs) and insertions and deletions (indels); rearrangements in ALK and ROS1; and SNVs for BRAF are not available AND when tissue-based CGP is infeasible [i.e., quantity not sufficient (QNS) for tissue-based CGP or invasive biopsy is medically contraindicated]

OR

At progression: For patients progressing on or after chemotherapy or immunotherapy who have not been tested for EGFR SNVs and indels; rearrangements in ALK and ROS1; and SNVs for BRAF, and for whom tissue-based CGP is infeasible; or for patients progressing on EGFR tyrosine kinase inhibitors (TKIs).

To avoid a delay in specimen processing, please provide a signed copy of the appropriate ABN for Medicare/Medicare Advantage patients when:

- Patient does not meet the coverage criteria: use InVisionFirst®-Lung Liquid Biopsy ABN – Diagnosis (https://neogenomics.com/sites/default/files/2021-07/InVisionFirst-Lung-Liquid-Biopsy-ABN-Diagnosis.pdf)
- Physician orders InVisionFirst®-Lung Liquid Biopsy concurrently with tissue testing that includes EGFR, BRAF, ALK, and/or ROS1: use InVisionFirst®-Lung Liquid Biopsy ABN – Concurrent Testing

NEO GENOMICS